

INDEPENDENT AUDITOR'S REPORT

To The Members of Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited ("the Company"), which comprise the Balance Sheet as at 31 March 2022, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2022, and its profit, total comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

- The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's report, Management Discussion & Analysis but does not include the financial statements and our auditor's report thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

MT

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.

95

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit, we report, that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Cash Flows and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31 March 2022, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2022, from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

mt

- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of Section 197 of the Act.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company;
 - iv.
 - (a) The management has represented that, to the best of its knowledge and belief, as disclosed in the financial statements, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (b) The management has represented, that, to the best of its knowledge and belief, as disclosed in the financial statements, no funds (which are material either individually or in the aggregate) have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (c) Based on the audit procedures that has been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
 - v. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.

95

Deloitte Haskins & Sells

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S. Trasi
(Partner)
(Membership No. 211095)
(UDIN: 22211095AJRIWK2018)

Bengaluru, 20 May 2022

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited ("the Company") as of 31 March 2022, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



Meaning of Internal Financial Controls Over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2022, based on the criteria for internal financial control over financial reporting established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S. Trasi

(Partner)
(Membership No. 211095)
(UDIN: 22211095AJRIWK2018)

Bengaluru, 20 May 2022

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that

(i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment and relevant details of right-of-use assets.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) The Company has a program of verification of property, plant and equipment, and right-of-use assets so to cover all the items in a phased manner over a period of 2 years, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain property, plant and equipment and right-of-use assets were due for verification during the year and were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) The Company does not have any immovable properties and hence reporting under clause (i)(c) of the Order is not applicable.

(d) The Company has not revalued any of its property, plant and equipment (including right of use assets) and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at 31 March 2022, for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

(ii)

(a) The inventories were physically verified during the year by the management at reasonable intervals. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification by the management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories when compared with books of account.

(b) According to the information and explanations given to us, the Company has not been sanctioned working capital limits in excess of INR 5 crores, in aggregate, at any point of time during the year, from banks or financial institutions on the basis of security of current assets. Hence, reporting on the quarterly returns or statements filed by the Company with such banks or financial institutions is not applicable.



(iii) The Company has made investments in companies and granted unsecured loans to other parties during the year, in respect of which:

(a) The Company has provided unsecured loans during the year and details of which are given below:

	Loans (INR lakhs)
A. Aggregate amount granted / provided during the year:	
- Others	25
B. Balance outstanding as at balance sheet date: *	
- Others	25

(b) The investments made, and the terms and conditions of the grant of all the above-mentioned loans provided during the year are, in our opinion, prima facie, not prejudicial to the Company's interest.

(c) In respect of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the principal amounts and interest are not due as at the balance sheet date.

(d) According to information and explanations given to us and based on the audit procedures performed, in respect of loans granted by the Company, there is no overdue amount remaining outstanding as at the balance sheet date.

(e) None of the loans granted by the Company have fallen due during the year.

(f) According to information and explanations given to us and based on the audit procedures performed, the Company has not granted any loans either repayable on demand or without specifying any terms or period of repayment during the year. Hence, reporting under clause (iii)(f) of the Order is not applicable.

The Company has not provided any guarantee or security or granted any advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties.

(iv) The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees, and securities provided, as applicable.

(v) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause (v) of the Order is not applicable.

(vi) The maintenance of cost records has been specified by the Central Government under Section 148(1) of the Companies Act, 2013 in respect of healthcare services rendered. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

97

(vii) In respect of statutory dues:

- (a) Undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, cess and other material statutory dues applicable to the Company have been regularly deposited by it with the appropriate authorities in all cases during the year.

There were no undisputed amounts payable in respect of Goods and Services tax, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, cess and other material statutory dues in arrears as at 31 March 2022, for a period of more than six months from the date they became payable.

- (b) Details of statutory dues referred to in sub-clause (a) above which have not been deposited as on 31 March 2022, on account of disputes are given below:

Name of Statute	Nature of Dues	Forum where Dispute is Pending	Period to which the Amount Relates (financial year)	Amount involved (INR lakhs)	Amount remaining unpaid (INR lakhs)
APVAT Act and Rules 2005	Value Added Tax	Deputy Commissioner (CT)	2013-14 to 2015-16	16.99	12.74

- (viii) There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.

(ix)

- (a) In our opinion, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries.

gm

Deloitte Haskins & Sells

- (x)
- (a) The Company has not issued any of its securities (including debt instruments) during the year and hence reporting under clause (x)(a) of the Order is not applicable.
 - (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.
- (xi)
- (a) To the best of our knowledge, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
 - (b) To the best of our knowledge, no report under sub-section (12) of Section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
 - (c) As represented to us by the management, there were no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- (xiii) In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.
- (xiv)
- (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
 - (b) We have considered, the internal audit reports issued to the Company during the year and the draft of the internal audit reports issued after the balance sheet date for the period under audit.
- (xv) In our opinion, during the year, the Company has not entered into any non-cash transactions with any of its directors or directors of its holding company or subsidiary companies or persons connected with its directors and hence provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi)
- (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause (xvi)(a), (b) and (c) of the Order is not applicable.
 - (b) The Group does not have any core investment company as part of the group and accordingly reporting under clause (xvi)(d) of the Order is not applicable.
- (xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.



Deloitte Haskins & Sells

- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of Section 135 of the said Act. Accordingly, reporting under clause (xx) of the Order is not applicable for the year.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S. Trasi
(Partner)

(Membership No. 211095)
(UDIN: 22211095AJRIWK2018)

Bengaluru, 20 May 2022

Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Balance sheet as at 31 March 2022
All amounts in INR lakhs, unless otherwise stated

Particulars	Note	As at 31 March 2022	As at 31 March 2021
Assets			
Non-current assets			
Property, plant and equipment	4	8,661.79	8,884.71
Right-of-use assets	31	2,618.10	2,719.75
Other intangible assets	5	43.00	44.26
Financial assets			
Investments	6	5,479.50	3,002.85
Other financial assets	10	297.08	272.69
Income tax assets (net)	28	894.70	653.50
Deferred tax assets (net)	28	374.31	215.98
Other non-current assets	11	77.74	3.09
Total non-current assets		18,446.22	15,796.83
Current assets			
Inventories	7	315.88	259.69
Financial assets			
Investments	6	602.17	2,367.77
Trade receivables	8	1,294.59	1,105.73
Cash and cash equivalents	9	61.10	724.80
Other financial assets	10	111.00	138.18
Other current assets	11	229.18	191.97
Total current assets		2,613.92	4,788.14
Total assets		21,060.14	20,584.97
Equity and liabilities			
Equity			
Equity share capital	12	1,078.58	1,078.58
Other equity	13	11,217.16	9,729.10
Equity attributable to owners of the Company		12,295.74	10,807.68
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	14	1,400.41	1,974.50
Lease liabilities	31	3,879.05	3,909.61
Other financial liabilities	17	37.00	-
Provisions	16	319.10	226.99
Total non-current liabilities		5,635.56	6,111.10
Current liabilities			
Financial liabilities			
Borrowings	14	499.10	965.12
Lease liabilities	31	118.34	100.23
Trade payables		-	-
- Total outstanding dues of micro and small enterprises	15	2,108.90	2,244.94
- Total outstanding dues of creditors other than micro and small enterprises	17	162.65	171.95
Other financial liabilities	18	174.72	133.14
Other current liabilities	16	65.13	50.81
Provisions		3,128.84	3,666.19
Total current liabilities		3,128.84	3,666.19
Total equity and liabilities		21,060.14	20,584.97

The accompanying notes form an integral part of these financial statements.

Note I to 41

As per our report of even date attached.

for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number: 008072S

Judeep S. Trasi
Judeep S. Trasi
Partner
Membership No.: 211095
Bengaluru
20 May 2022



for and behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U73100AP1995PTC020491

Dr. P. Ramesh Babu
Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
20 May 2022

Mr. M.S. Rama Mohan Rao
Mr. M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
20 May 2022

S. Suggula Hari Krishna
S. Suggula Hari Krishna
Chief Financial Officer
Vijayawada
20 May 2022

S. Nagesh Kumar
S. Nagesh Kumar
Company Secretary
Membership No. A33490
Vijayawada
20 May 2022

Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Statement of profit and loss for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

Particulars	Note	For the year ended 31 March 2022	For the year ended 31 March 2021
Income			
Revenue from operations	19	21,280.22	15,298.90
Other income	20	436.52	463.25
Total income		21,716.74	15,762.15
Expenses			
Purchases of medicines and consumables	21	5,341.25	3,019.36
Changes in inventories	22	(56.19)	403.54
Professional fees paid to doctors	23	4,727.99	3,114.98
Employee benefits expense	24	5,513.03	5,106.70
Finance costs	25	486.91	679.27
Depreciation and amortisation expenses	26	1,201.52	1,254.80
Other expenses	27	2,862.77	2,533.13
Total expenses		20,077.28	16,111.78
Profit / (Loss) before tax		1,639.46	(349.63)
Tax expense	28		
Current tax		310.72	-
Current tax for earlier years		-	(10.80)
Deferred tax		(158.61)	515.63
Total Tax expense		152.11	504.83
Profit / (Loss) for the year		1,487.35	(854.46)
Other comprehensive income			
Items that will not be reclassified subsequently to profit or loss			
Remeasurement of net defined benefit liability		0.99	29.07
Income tax relating to items that will not be reclassified to profit or loss		(0.28)	(8.09)
Total comprehensive income / (loss) for the year		1,488.06	(833.48)
Earnings/ (Loss) per share (equity share of face value of INR. 10 each)			
Basic	30	13.79	(7.92)
Diluted	30	13.79	(7.92)

The accompanying notes form an integral part of these financial statements.

Note 1 to 41

As per our report of even date attached

for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number: 008072S

Jaldeep S. Trasi
Partner
Membership No.: 211095
Bengaluru
20 May 2022



for and behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U73100AP1995PTC020491

Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
20 May 2022

Mr. M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
20 May 2022

CA. Suggula Hari Krishna
Chief Financial Officer
Vijayawada
20 May 2022

S. Nagendra Kumar
Company Secretary
Membership No. A33490
Vijayawada
20 May 2022

Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Statement of Cash flows for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Cash flow from operating activities	1,487.35	(854.46)
Profit / (Loss) for the year		
<i>Adjustments for</i>		
Tax expense	152.11	504.83
Depreciation and amortisation expenses	1,201.52	1,254.80
Finance costs	486.91	679.27
Allowances for credit losses on financial assets	182.00	402.66
Bad debts written off	60.36	82.23
Gain on sale of investment (net)	(96.13)	(30.66)
Dividend on non-current investments	(319.54)	(191.72)
Share of profit in limited liability partnership	(30.00)	(30.00)
Net changes in fair value of financial assets measured at FVTPL	44.98	(42.82)
Interest income under the effective interest method	(11.03)	(8.58)
Loss on disposal of property, plant and equipment (net)	14.97	4.28
Loss on disposal of capital work in progress	-	2.74
Gain on reassessment of IND AS 116	(1.36)	(2.89)
Liabilities no longer required written back	(17.00)	(2.35)
Guarantee commission income	-	(1.47)
Operating cash flows before movements in working capital	3,155.14	1,765.86
Movements in working capital		
(Increase) / decrease in inventories	(56.19)	403.54
(Increase) / decrease in trade receivables	(431.22)	1,061.03
(Increase) / decrease in other financial assets	(1.86)	58.87
(Increase) in other current assets	(58.73)	(32.64)
(Decrease) in trade payables	(119.04)	(328.03)
Increase in other financial liabilities	106.84	13.63
Increase / (decrease) in provisions	106.43	(35.89)
Increase / (decrease) in other liabilities	41.58	(88.22)
Cash generated from operating activities	2,742.95	2,818.15
Taxes paid, net of refund received	(550.94)	1,401.29
Net cash generated from operating activities (A)	2,192.01	4,219.44
Cash flows from investing activities		
Acquisition of property, plant and equipment	(986.49)	(288.24)
Proceeds on disposal of property, plant and equipment	42.70	4.11
Purchase of investments	(659.90)	(1,139.64)
Movement in other bank balances and restricted deposits	3.29	0.80
Dividend received	319.54	191.72
Share of profit in limited liability partnership	30.00	30.00
Advance towards capital contribution in Aster Ramesh Duhita LLP	-	(8.35)
Interest received	13.75	2.27
Net cash used in investing activities (B)	(1,237.11)	(1,207.33)
Cash flow from financing activities		
Secured borrowings availed	917.07	133.71
Secured borrowings repaid	(1,956.54)	(2,052.59)
Payment of lease liabilities	(444.43)	(460.79)
Finance cost	(134.71)	(326.75)
Net cash used in financing activities (C)	(1,618.61)	(2,706.42)
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(663.70)	305.69
Cash and cash equivalents at the beginning of the year	724.80	419.11
Cash and cash equivalents at the end of the year (refer Note 9)	61.10	724.80



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Statement of Cash flows for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

Changes in liabilities arising from financing activities for the year ended 31 March 2022

Particulars	As at 01 April 2021	Cash inflows / Impact of Ind AS 116	Cash outflows	Non-cash changes Fair value/other changes	Foreign exchange	As at 31 March 2022
Borrowings	2,939.62	917.07	(1,956.54)	(0.64)	-	1,899.51
Lease liabilities	4,009.84	-	(444.43)	431.98	-	3,997.39
Total	6,949.46	917.07	(2,400.97)	431.34	-	5,896.90

Changes in liabilities arising from financing activities for the year ended 31 March 2021

Particulars	As at 01 April 2020	Cash inflows / Impact of Ind AS 116	Cash outflows	Non-cash changes Fair value/other changes	Foreign exchange	As at 31 March 2021
Borrowings	4,857.05	133.71	(2,052.59)	1.45	-	2,939.62
Lease liabilities	4,157.17	-	(460.79)	313.46	-	4,009.84
Total	9,014.22	133.71	(2,513.38)	314.91	-	6,949.46

The accompanying notes form an integral part of these financial statements

Note 1 to 41

As per our report of even date attached

for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number: 008072S

Jaldeep S. Trasi
Partner
Membership No. 211095
Bengaluru
20 May 2022



for and behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U73100AP1995PTC020491

Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
20 May 2022

Mr. M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
20 May 2022

CA. Suggula Hari Krishna
Chief Financial Officer
Vijayawada
20 May 2022

S. Nagendra Kumar
Company Secretary
Membership No. A33490
Vijayawada
20 May 2022

Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Statement of changes in equity for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

A. Equity share capital

Particulars	Note	Number of equity shares (in lakhs)	Amount
Balance as at 1 April 2020	12	107.86	1,078.58
Changes in equity share capital during 2020-21		-	-
Balance as at 31 March 2021	12	107.86	1,078.58
Changes in equity share capital during 2021-22		-	-
Balance as at 31 March 2022		107.86	1,078.58

B. Other equity

Particulars	Reserves and surplus (Refer Note 13)			Items of other comprehensive income (Refer Note 13)		Total other equity attributable to equity holders of the Company
	Securities premium	Retained earnings	Capital redemption reserve	Remeasurement of net defined benefit liability/(asset), net of tax		
Balance as at 1 April 2020	7,454.54	3,068.04	40.00	-	-	10,562.58
(Loss) for the year	-	(854.46)	-	-	-	(854.46)
Other comprehensive income for the year, net of tax	-	-	-	-	20.98	20.98
Total comprehensive income / (loss)	-	(854.46)	-	-	20.98	(833.48)
Balance as at 31 March 2021	7,454.54	2,213.58	40.00	-	20.98	9,729.10
Balance as at 1 April 2021	7,454.54	2,213.58	40.00	-	20.98	9,729.10
Profit for the year	-	1,487.35	-	-	-	1,487.35
Other comprehensive income for the year, net of tax	-	-	-	-	0.71	0.71
Total comprehensive income	-	1,487.35	-	-	0.71	1,488.06
Balance as at 31 March 2022	7,454.54	3,700.93	40.00	-	21.69	11,217.16

The accompanying notes form an integral part of these financial statements

Note 1 to 41

As per our report of even date attached for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number: 008072S

Jaldeep S. Trasi
Jaldeep S. Trasi
Partner

Membership No. 211095
Bengaluru
20 May 2022



for and behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U71100AP1993PTC020491

Dr. P. Ramesh Reddy
Dr. P. Ramesh Reddy
Managing Director
DIN: 01879436
Vijayawada
20 May 2022

Mr. M.S. Rama Mohan Rao
Mr. M.S. Rama Mohan Rao
Chairman and Director
DIN: 02156742
Vijayawada
20 May 2022

S. Sugula Hari Krishna
S. Sugula Hari Krishna
Chief Financial Officer
Vijayawada
20 May 2022

S. Nageswara Kumar
S. Nageswara Kumar
Company Secretary
Membership No. A33686
Vijayawada
20 May 2022

Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

1. Company overview

Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited ("the Company") is a company domiciled in India, with its registered office at Vijayawada, Andhra Pradesh. The Company is engaged in the business of rendering medical and healthcare services, participating in clinical studies and conducting training programs and services primarily in Vijayawada and Guntur. Aster DM Healthcare Limited is the Holding Company.

2. Basis of preparation

A. Statement of compliance

These financial statements have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as per the Companies (Indian Accounting Standards) Rules, 2015, as amended, and the relevant amended rules prescribed under Section 133 of the Companies Act, 2013 (the 'Act'), read with relevant rules issued thereunder.

On 24 March 2021 the Ministry of Corporate Affairs (MCA) through a notification, amended Schedule III of the Companies Act, 2013 and the amendments are applicable for financial periods commencing from 1 April 2021. The Company has evaluated the effect of the amendments on its financial statements and complied with the same.

Pursuant to Rule 6 of the Companies (Accounts) Rules, 2014 (Amended Rules), the Company has not presented consolidated financial statements as its Parent Company (Aster DM Healthcare Limited) is incorporated in India and presenting the consolidated financial statements as required by the Companies Act, 2013.

These financial statements were authorised for issue by the Company's Board of Directors on 20 May 2022.

Details of the Company's significant accounting policies are included in Note 3.

B. Functional and presentation currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are presented in Indian Rupees in lakhs, unless otherwise stated.

C. Basis of measurement

These financial statements have been prepared on the historical cost basis except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities, and
- ii. Net defined benefit (asset)/ liability

D. Use of estimates and judgements

In preparing these financial statements, the Management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed by the Management on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

Information about judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment during the year ended 31 March 2022 is included in the following notes:

- Note 4 and 5 - Measurement of useful life and residual value of property, plant and equipment and intangible assets.
- Note 6 - Impairment of investment in subsidiaries and associates.
- Note 28 - Recognition of deferred tax asset: availability of future taxable profit against which tax losses carried forward can be used.
- Note 29 - Recognition and measurement of provisions and contingencies: key assumptions about the likelihood and magnitude of an outflow of resources.
- Note 31 - Leases.
- Note 33 - Measurement of defined benefit obligations: key actuarial assumptions.
- Note 36 - Impairment of financial assets.

Estimation uncertainties relating to COVID-19

The Company adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption and has considered available internal and external information up to the date of approval of the financial statements by the Board of Directors. The Company has used the principles of prudence in applying judgements, estimates and assumptions including sensitivity analysis and the Company has evaluated impact of the pandemic in assessing the recoverability of property plant and equipment (including capital work-in-progress), investments, intangibles, inventories, receivables and other assets based on its review of current indicators of future economic conditions. Based on current estimates, including the availability of financing facilities for maintaining liquidity, the Company expects to fully recover the carrying amount of these assets. The eventual outcome of impact of the global health pandemic may be different from that which has been estimated as on the date of approval of these financial statements. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial statements as and when these material changes to economic conditions arise.

a. Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Company has an established control framework with respect to the measurement of fair values. Significant valuation issues are reported to the Company's audit committee.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices), and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the following notes:

- Financial instruments
- Fair value of property, plant and equipment and intangible assets



E. Recent accounting pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 23, 2022, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2022, applicable from April 1, 2022, as below

a) Ind AS 103 - Reference to Conceptual Framework

The amendments specify that to qualify for recognition as part of applying the acquisition method, the identifiable assets acquired and liabilities assumed must meet the definitions of assets and liabilities in the Conceptual Framework for Financial Reporting under Indian Accounting Standards (Conceptual Framework) issued by the Institute of Chartered Accountants of India at the acquisition date. These changes do not significantly change the requirements of Ind AS 103. The Company does not expect the amendment to have any significant impact in its financial statements

b) Ind AS 16 - Proceeds before intended use

The amendments mainly prohibit an entity from deducting from the cost of property, plant and equipment amounts received from selling items produced while the company is preparing the asset for its intended use. Instead, an entity will recognise such sales proceeds and related cost in profit or loss. The Company does not expect the amendments to have any significant impact in its recognition of its property, plant and equipment in its financial statements

c) Ind AS 37 - Onerous Contracts - Costs of fulfilling a contract

The amendments specify that the 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to a contract can either be incremental costs of fulfilling that contract (examples would be direct labour, materials) or an allocation of other costs that relate directly to fulfilling contracts. The amendment is essentially a clarification and the Company does not expect the amendment to have any significant impact in its financial statements

d) Ind AS 109 - Annual improvements to Ind AS (2021)

The amendment clarifies which fees an entity includes when it applies the '10 percent' test of Ind AS 109 in assessing whether to derecognise a financial liability. The Company does not expect the amendment to have any significant impact in its financial statements

3. Significant accounting policies

3.1 Property, plant and equipment

i. Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and accumulated impairment losses, if any

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment

Any gain or loss on disposal of an item of property, plant and equipment is recognised in the statement of profit and loss

Advances paid towards the acquisition of property, plant and equipment, outstanding at each balance sheet date are shown under other non-current assets. The cost of property, plant and equipment not ready for its intended use at each balance sheet date are disclosed as capital work-in-progress

ii. Subsequent expenditure and derecognition

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss

iii. Depreciation

Depreciation on property, plant and equipment are provided on the straight-line method over the useful lives of the assets estimated by the Management. Depreciation for assets purchased / sold during a period is proportionately charged. Leasehold improvements are amortized over the lease term or useful lives of assets, whichever is lower. The estimated useful lives of items of property, plant and equipment for the current and comparative years are as follows:

Class of assets	Useful life (in years)
Office equipment	5
Medical equipment *	13
Motor vehicles *	8-10
Computer equipment	3-6
Furniture and fixtures *	10
Electrical equipment	10

* For the above-mentioned classes of assets, the Company believes that the useful lives as given above best represent the useful lives of these assets based on internal assessment and supported by technical advice, where necessary, which is different from the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate



3.2 Intangible assets

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Intangible assets are amortised over their respective individual estimated useful lives on a straight-line basis, commencing from the date the asset is available to the Company for its use and is included in depreciation and amortisation expenses in statement of profit and loss. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. The estimated useful life of software is 4 years.

The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognised in the statement of profit and loss as incurred.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in the statement of profit and loss when the asset is derecognised.

3.3 Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories comprises purchase price, and other cost incurred in bringing the inventories to their present location and condition. The Company uses the weighted average method to determine the cost of inventory consisting of medicines and medical consumables.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. The comparison of cost and net realisable values is made on an item-by-item basis.

3.4 Impairment

i. Impairment of financial assets

The Company recognises loss allowances for expected credit losses ('ECL') on financial assets measured at amortised cost.

At each reporting date, the Company assesses whether financial assets carried at amortised cost are credit impaired. A financial asset is 'credit impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

The Company always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtors and an analysis of the debtors' current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate, and an assessment of both the current as well as the forecast direction of conditions at the reporting date.

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

Measurement of expected credit losses

Expected credit losses are a probability weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e., the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

Presentation of allowance for expected credit losses in the balance sheet:

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write off.

ii. Impairment of non-financial assets

The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated to determine the extent of impairment loss, if any.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount i.e., the higher of the fair value less cost to sell and the value-in-use is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the statement of profit and loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset.

An impairment loss is reversed in the statement of profit and loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.



3.5 Employee benefits

Short-term employee benefits

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus and ex-gratia. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid e.g. under short-term cash bonus, if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the amount of obligation can be estimated reliably.

Post-employment benefits

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions and will have no legal or constructive obligation to pay further amounts. The Company makes specified monthly contributions towards Government administered provident fund scheme. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in the statement of profit and loss in the periods during which the related services are rendered by employees.

Defined Benefit plans

Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees.

The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method.

Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses are recognised in other comprehensive income (OCI) in the period in which they occur. Remeasurements of the net defined benefit liability (asset) recognised in other comprehensive income shall not be reclassified to the statement of profit and loss in a subsequent period. However, the Company transfers those amounts recognised in other comprehensive income within equity. The Company determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognised in the statement of profit and loss.

Other long term employee benefits

The Company's net obligation in respect of long-term employee benefits other than post-employment benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value, and the fair value of any related assets is deducted. The obligation is measured on the basis of an annual independent actuarial valuation using the projected unit credit method. Remeasurement gains or losses are recognised in other comprehensive income in the period in which they arise.

3.6 Provisions (other than employee benefits)

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

3.7 Revenue

Revenue from contract with customers

The Company generates revenue from rendering of medical and healthcare services, sale of medicines and other related activities. Ind AS 115, Revenue from Contracts with Customers, establishes a comprehensive framework for determining whether, how much and when revenue is recognised. Under Ind AS 115, revenue is recognised when a customer obtains control of the goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those products or services. In calculating the variable considerations, the Company considers the nature and coverage through insurance and other parties, the history of adjustments and rejections, and the probability of rejections, discounts, rebates, price concessions, or other similar items.

Disaggregation of revenue

The Company disaggregates revenue from hospital services (medical and healthcare services), sale of medicines and other operating income. The Company believes that this disaggregation best depicts how the nature, amount, timing and certainty of Company's revenues and cash flows are affected by industry, market and other economic factors.

Contract balances

The Company classifies the right to consideration in exchange for sale of services where invoice is raised as trade receivables, where invoice has not been raised as unbilled revenue and advance consideration as advance from customers.

Performance obligations and revenue recognition policies

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognises revenue when it transfers control over a good or service to a customer. The following details provide information about the nature and timing of the satisfaction of performance obligations in contracts with customers, including significant payment terms, and the related revenue recognition policies.



3.7 Revenue (continued)

(a) Medical and healthcare services

The Company's revenue from medical and healthcare services comprises of income from hospital services.

Revenue from hospital services to patients is recognised as revenue when the related services are rendered unless significant future uncertainties exist. Revenue is also recognised in relation to the services rendered to the patients who are undergoing treatment/ observation on the balance sheet date to the extent of the services rendered. Revenue is recognised net of discounts, concessions given to the patients and estimated disallowances for patients covered under insurance.

Unbilled receivable represents value to the extent of medical and healthcare services are rendered to the patients who are undergoing treatment/observation on the balance sheet date and is not billed as at the balance sheet date.

(b) Sale of medicines

Revenue from sale of medical consumables and medicines within the hospital premises is recognised when the control in the goods are transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection. The amount of revenue recognised is net of sales returns, taxes and duties, wherever applicable.

(c) Other operating income

The Company's revenue from other operating income comprises primarily of canteen sales (sales of food and beverages), revenue from courses conducted at the hospital, income from revenue sharing agreements.

Revenue from services rendered is based on the agreements/arrangements with the customers as the service is performed. Income from sale of food and beverages is recognised at a point in time when control is transferred.

3.8 Foreign currency transactions

Transactions in foreign currencies are translated into the functional currency of the Company at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences are recognised in the statement of profit and loss.

3.9 Leases

Determining whether an arrangement contains a lease

At inception of an arrangement, it is determined whether the arrangement is or contains a lease. At inception or on reassessment of the arrangement that contains a lease, the payments and other consideration required by such an arrangement are separated into those for the lease and those for other elements on the basis of their relative fair values.

i. Company as a lessee

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets are subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date, residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in the statement of profit and loss.

The Company has elected not to apply the requirements of Ind AS 116, Leases, to short-term leases of all assets that have a lease term of 12 months or less. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term.

Variable rents that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs and are included in the line "Other expenses" in the statement of profit and loss.



3.9 Leases (continued)

ii. Company as a lessor

At the inception of the lease the Company classifies each of its leases as either an operating lease or a finance lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant periodic rate of return on the lessor's net investment in the lease.

Amounts due from lessees under finance leases are recognised as receivables at the amount of the Company's net investment in the leases. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset. If a head lease is a short-term lease to which the Company applies the exemption described above, then it classifies the sub-lease as an operating lease.

If an arrangement contains lease and non-lease components, the Company applies Ind AS 115 Revenue from contracts with customers to allocate the consideration in the contract.

iii. Impact of COVID-19

The Company does not foresee any large-scale contraction in demand which could result in significant down-sizing of its employee base rendering the physical infrastructure redundant. The leases that the Company has entered with lessors are long term in nature and changes in terms of those leases expected due to the COVID-19 are not expected to have impact in the financial statements for the year ended 31 March 2022.

The Company had adopted the amendments to Ind AS 116 for the first time in the previous year. The amendments provide practical relief to lessees in accounting for rent concessions occurring as a direct consequence of COVID-19, by introducing a practical expedient to Ind AS 116. The practical expedient permits a lessee to elect not to assess whether a COVID-19-related rent concession is a lease modification. A lessee that makes this election shall account for any change in lease payments resulting from the COVID-19-related rent concession the same way it would account for the change applying Ind AS 116 if the change were not a lease modification.

The practical expedient applies only to rent concessions occurring as a direct consequence of COVID-19 and only if all of the following conditions are met

(a) The change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change;

(b) Any reduction in lease payments affects only payments originally due on or before 30 June 2022 (a rent concession meets this condition if it results in reduced lease payments on or before 30 June 2022 and increased lease payments that extend beyond 30 June 2022), and

(c) There is no substantive change to other terms and conditions of the lease.

The Company had applied the practical expedient retrospectively to all eligible rent concessions in the previous year.

3.10 Recognition of dividend income, interest income or interest expense

Dividend income is recognised in the statement of profit and loss on the date on which the right to receive payment is established.

Interest on deployment of surplus funds is recognized using the time proportionate method, based on the transactional interest rates.

Interest income or expense is recognised using the effective interest method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to the gross carrying amount of the financial asset or the amortised cost of the financial liability.

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability.

3.11 Income tax

Income tax comprises current and deferred tax. It is recognised in statement of profit and loss except to the extent that it relates to an item recognised directly in equity or in other comprehensive income.

i. Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

A provision is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on the judgement of tax professionals within the Company supported by previous experience in respect of such activities and in certain cases based on specialist independent tax advice.



3.11 Income tax (continued)

ii. Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases used for taxation purposes. Deferred tax is also recognised in respect of carried forward tax losses and tax credits. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be utilised. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

3.12 Borrowing cost

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings) to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset until such time as the asset is substantially ready for their intended use or sale. Other borrowing costs are recognised as an expense in the period in which they are incurred.

3.13 Financial instruments

i. Recognition and initial measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value, except for trade receivables that do not have a significant financing component which are measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss - FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in the statement of profit and loss.

ii. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as either at amortised cost, FVTPL or fair value through other comprehensive income (FVOCI).

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at investment level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for each of such investments and the operation of those policies in practice. These include whether Management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;

- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.



3.13 Financial instruments (continued)

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g., liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g., non-recourse features)

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in statement of profit and loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in statement profit and loss. Any gain or loss on derecognition is recognised in statement of profit and loss.
Equity investments at FVOCI	These assets are subsequently measured at fair value. Dividends are recognised as income in statement profit and loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to statement of profit and loss.

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in statement of profit and loss.

Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in statement of profit and loss. Any gain or loss on derecognition is also recognised in statement of profit and loss.

iii. Derecognition

Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire. The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in statement of profit and loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.



3.14 Earnings / (Loss) per share

The basic earnings / (loss) per share ('EPS') is computed by dividing the net profit / (loss) after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year

Diluted earnings per share is computed by dividing the profit/(loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares

Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date. In computing dilutive earnings per share, only potential equity shares that are dilutive, i.e., which reduces earnings per share or increases loss per share are included. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits/reverse share splits and bonus shares, as appropriate

3.15 Cash-flow statement

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities of the Company are segregated.

3.16 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand and short-term deposits with an original maturity of three months or less which are subject to insignificant risk of changes in value

3.17 Segment reporting

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Medical and Healthcare Services'.

3.18 Operating cycle

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

4 Property, plant and equipment

Particulars	Leasehold improvements (Refer Notes (b) and (c) below)	Medical equipment	Electrical equipment	Office equipment	Computer equipment	Furniture and fixtures	Motor Vehicles	Total
Gross carrying value								
Balance as at 1 April 2020	5,880.81	5,547.34	1,130.35	887.32	179.23	580.98	386.45	14,592.48
Additions	29.88	126.31	44.52	18.20	16.58	17.81	-	253.30
Disposals	(0.05)	(6.72)	(18.89)	(15.76)	(5.76)	(59.96)	(3.65)	(110.79)
Balance as at 31 March 2021	5,910.64	5,666.93	1,155.98	889.76	190.05	538.83	382.80	14,734.99
Balance as at 1 April 2021	5,910.64	5,666.93	1,155.98	889.76	190.05	538.83	382.80	14,734.99
Additions	2.43	539.90	141.75	30.62	61.60	43.18	7.77	827.25
Disposals	-	(154.30)	(0.17)	(1.12)	(31.07)	-	(93.87)	(280.53)
Balance as at 31 March 2022	5,913.07	6,052.53	1,297.56	919.26	220.58	582.01	296.70	15,281.71
Accumulated depreciation								
Balance as at 1 April 2020	1,395.58	1,626.41	560.23	831.09	112.01	284.29	161.74	4,971.35
Charge for the year	205.83	485.82	121.79	20.45	41.50	53.59	52.35	981.33
Eliminated on disposals	(0.05)	(2.81)	(18.87)	(15.74)	(5.75)	(55.53)	(3.65)	(102.40)
Balance as at 31 March 2021	1,601.36	2,109.42	663.15	835.80	147.76	282.35	210.44	5,850.28
Balance as at 1 April 2021	1,601.36	2,109.42	663.15	835.80	147.76	282.35	210.44	5,850.28
Charge for the year	216.49	515.58	113.95	18.55	37.99	52.88	45.88	1,001.32
Eliminated on disposals	-	(115.94)	-	(1.12)	(30.94)	-	(83.68)	(231.68)
Balance as at 31 March 2022	1,817.85	2,509.06	777.10	853.23	154.81	335.23	172.64	6,619.92
Net carrying value								
As at 31 March 2022	4,095.22	3,543.47	520.46	66.03	65.77	246.78	124.06	8,661.79
As at 31 March 2021	4,309.28	3,557.51	492.83	53.96	42.29	256.48	172.36	8,884.71

a) For details of property, plant and equipment pledged, refer Note 14.

b) The Company has a hospital situated in Gunadala, Vijayawada which is located on land that has been taken on a sub-lease from Mrs. P. Maha Lakshmi, wife of the Managing Director who had taken it on lease from M/s. Loyola College Society ("Society") vide a lease agreement dated 21 September 2004. The lease was initially taken for a period of 9 years and 11 months which was renewed for an additional period of 15 years and 1 month. This additional lease period expired on 31 January 2019.

At the time of entering into the initial lease, a separate intent letter dated 1st May 1994 was also issued by the Society stating that the Company will have an option to request for renewal of lease for a further period of 25 years from 31 January 2019 based on such terms and conditions as may be mutually agreed. In accordance with this intent letter, the Management has made an application dated 03 July 2018 to the Society to extend the lease beyond 31 January 2019. However, the Society rejected this application and has issued a notice to the Company to vacate the premises and to hand over the entire building and structure to the Society.

Aggrieved by this, the Management has filed a legal case against the Society and the matter is presently sub-judice. The Company had received injunction orders in its favour from the Court of the II. Addl. District Judge vide its orders dated 28 June 2021. Based on legal advice, the Management is of the view that it has a good case to seek renewal of the lease and does not expect any impact of this matter on the future operations of the hospital.

c) Leasehold improvements include super structures and interior works constructed on leased land disclosed as buildings previously. The Company depreciates these over the lease term of the land and original building



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

5 Other Intangibles assets

Particulars	Computer software
Gross carrying value	
Balance as at 1 April 2020	107.84
Additions	21.83
Disposals	-
Balance as at 31 March 2021	129.67
Balance as at 1 April 2021	129.67
Additions	20.03
Disposals	(2.16)
Balance as at 31 March 2022	147.54
Accumulated amortisation	
Balance as at 1 April 2020	68.90
Amortisation for the year	16.51
Eliminated on disposals	-
Balance as at 31 March 2021	85.41
Balance as at 1 April 2021	85.41
Amortisation for the year	21.22
Eliminated on disposals	(2.09)
Balance as at 31 March 2022	104.54
Net carrying value	
As at 31 March 2022	43.00
As at 31 March 2021	44.26



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

6 Investments

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current investments, unquoted		
<i>Investments in equity instruments of subsidiaries (at cost)</i>		
Investment in Sanghamitra Hospitals Private Limited		
44,92,308* (31 March 2021: 31,95,388) equity shares of INR 10 each	5,391.75	2,915.10
Investment in Aster Ramesh Duhita LLP		
51% of the total capital amounting to INR 47.75 lakhs	47.75	47.75
(31 March 2021: 51% of the total capital amounting to INR 47.75 lakhs)		
Investment in Komali Fertility Centre LLP		
50% of the total capital amounting to INR 40 lakhs	40.00	40.00
(31 March 2021: 50% of the total capital amounting to INR 40 lakhs)		
Total	5,479.50	3,002.85
Aggregate carrying amount of unquoted investments	5,479.50	3,002.85
Current investments, quoted		
<i>Investment in Mutual Funds - Quoted investments (non-trade at fair value through profit or loss)</i>		
Reliance Equity Hybrid Fund- Segregated Portfolio - I	0.05	0.05
Reliance Liquid Fund - Treasury Plan	602.12	794.11
[11,561 (31 March 2021: 15,779) units]		
Nippon India Money Market Fund	-	1,568.16
[Nil (31 March 2021: 48,690) units]		
Nippon India Balanced Advantage Fund	-	5.45
[Nil (31 March 2021: 4,279) units]		
Total	602.17	2,367.77
Aggregate carrying amount of quoted investments	602.17	2,367.77
Aggregate market value of quoted investments	602.17	2,367.77
Aggregate amount of impairment in the value of investments	-	-

* Includes 74,764 shares, which the Company is in the process of getting the same transferred in the name of the Company.

7 Inventories

Particulars	As at 31 March 2022	As at 31 March 2021
<i>(Valued at lower of cost and net realisable value)</i>		
Medicines and medical consumables	315.88	259.69
Total	315.88	259.69
For details of inventories pledged, refer Note 14.		

8 Trade receivables

Particulars	As at 31 March 2022	As at 31 March 2021
Current		
Considered good - unsecured	2,240.89	1,910.03
Less: loss allowance	(946.30)	(804.30)
Net trade receivables	1,294.59	1,105.73

For details of trade receivable pledged, refer Note 14.

The Company's exposure to credit and currency risks and loss allowances related to trade receivables are disclosed in Note 37.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

8.1 Trade receivables ageing schedule

Particulars	As at 31 March 2022	As at 31 March 2021
Undisputed trade receivables- considered good		
Outstanding for following periods from due date of payment		
Not due	603.20	792.44
Less than 6 months	1,079.80	210.93
6 months - 1 year	321.83	292.80
1-2 years	88.93	351.72
2-3 years	115.70	185.90
More than 3 years	31.43	76.24
Total	2,240.89	1,910.03

8.2 Loss allowance provision matrix- default rates applied at each reporting date

Particulars	As at 31 March 2022	As at 31 March 2021
Due date to 1 year	18.70% to 90.68%	36.11% to 57.04%
1-2 years	21.96% to 90.68%	40.09% to 81.78%
More than 2 years	90.68% to 100%	81.78% to 100%

8.3 Movement of Loss allowance

Particulars	As at 31 March 2022	As at 31 March 2021
Balance at the beginning of the year	804.30	401.64
Provision of loss allowance (net)	142.00	402.66
Balance at the end of the year	946.30	804.30

9 Cash and cash equivalents

Particulars	As at 31 March 2022	As at 31 March 2021
Balance with banks	21.51	690.91
Cash on hand	39.59	33.89
Total	61.10	724.80



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

10 Other financial assets

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current		
Rent deposits and other deposits^	214.21	188.36
Fixed deposits *	38.91	42.20
Advance towards capital contribution in Aster Ramesh Duhita LLP	43.91	39.36
Interest accrued on fixed deposits with banks	0.05	2.77
Total	297.08	272.69

Current

Unsecured, considered good

Rent deposits and other deposits^	13.39	10.63
Unbilled receivables	39.73	61.32
Advance to employees	57.88	66.23
Total	111.00	138.18

* The above deposits are maintained against guarantees issued by Banks and are restricted for periods exceeding 12 months as at the Balance Sheet date, which are marked as lien with Government authorities.

^ Includes deposits given to related parties. Refer Note 34.

Refer Note 15 with regard to the loan given to Dr. Ramesh Health and Educational Society.

11 Other assets

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current		
Prepaid expenses	23.75	2.23
Advance for capital goods	53.99	0.86
Total	77.74	3.09
Current		
Prepaid expenses	60.85	53.59
Advance for supply of goods and services	125.76	111.17
Other loans and advances	42.57	27.21
Total	229.18	191.97



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

12 Share capital

Particulars	As at 31 March 2022		As at 31 March 2021	
	Number of shares (in lakhs)	Amount	Number of shares (in lakhs)	Amount
Authorised				
Equity shares of INR 10 each	110.00	1,100.00	110.00	1,100.00
	110.00	1,100.00	110.00	1,100.00
Issued, subscribed and fully paid-up				
Equity shares of INR 10 each	107.86	1,078.58	107.86	1,078.58
Total	107.86	1,078.58	107.86	1,078.58

Refer Notes 12.1 to 12.8 below.

12.1 Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. All equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to shareholders' share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.

Failure to pay any amount called up on shares may lead to forfeiture of shares.

On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

12.2 Shares held by ultimate holding company

Particulars	As at 31 March 2022		As at 31 March 2021	
	Number of shares (in lakhs)	Amount	Number of shares (in lakhs)	Amount
<i>Equity shares of INR 10 each fully paid-up held by</i>				
Aster DM Healthcare Limited, Holding and Ultimate holding company	55.01	550.08	55.01	550.08

12.3 Details of shareholders holding more than 5% shares of the Company

Particulars	As at 31 March 2022		As at 31 March 2021	
	Number of shares (in lakhs)	% of holding	Number of shares (in lakhs)	% of holding
<i>Equity shares of INR 10 each fully paid-up held by</i>				
Aster DM Healthcare Limited	55.01	51.00%	55.01	51.00%
Dr. P. Ramesh Babu	21.74	20.16%	21.74	20.16%
P. Mahalakshmi	9.00	8.34%	9.00	8.34%
P. Raja Nishanth	5.95	5.52%	5.95	5.52%
P. Madhusmitha	5.82	5.39%	5.82	5.39%
P. Ravi Kiran	5.60	5.19%	5.60	5.19%

12.4 Details of shareholding of Promoters

Promoter name	Shares held as at 31 March 2022		Percentage change during the year ended 31 March 2022
	Number of shares	% of total shares	
Aster DM Healthcare Limited	55,00,771	51.00%	Nil
Dr. P. Ramesh Babu	21,74,404	20.16%	
P. Mahalakshmi	9,00,000	8.34%	
P. Raja Nishanth	5,95,000	5.52%	
P. Madhusmitha	5,81,500	5.39%	
P. Ravi Kiran	5,60,000	5.19%	
Dr. P. Mahendra Babu	3,10,000	2.87%	
P. V. Ravi Kishore	40,000	0.37%	
P. Subba Rao	30,000	0.28%	
K. Madhumati	30,000	0.28%	
P. Murali Mohan	20,000	0.20%	
M. Sailaja	9,000	0.09%	
P. Manmohan Krishna	7,500	0.08%	
P. Ashok Kumar	4,400	0.04%	
P. Vasundhara Devi	2,500	0.02%	
P. Usha Rani	2,500	0.02%	
P. Padmasri	2,500	0.02%	
R. Radha Bai	2,500	0.02%	
R. V. Chalapathi Rao	2,500	0.02%	
P. S. Kamaladevi	2,500	0.02%	
P. Sree Lakshmi	2,500	0.02%	
P. Madhuri	2,250	0.02%	
P. Gopi Krishna	1,000	0.01%	
M.S. Rama Mohan Rao			



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

12.5 Shares reserved for issue under options and contracts: Nil

12.6 Details of bonus shares issued during the past 5 years immediately preceeding 31 March 2022: Nil

12.7 Details of shares issued for consideration other than for cash during the past 5 years immediately preceeding 31 March 2022: Nil

12.8 Details of buyback of shares during the past 5 years immediately preceeding 31 March 2022: Nil

13 Other equity

Particulars	As at 31 March 2022	As at 31 March 2021
Reserves and Surplus		
Securities premium	7,454.54	7,454.54
- Used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.		
Capital redemption reserve	40.00	40.00
-A statutory reserve created to the extent of sum equal to the nominal value of the share capital extinguished on buyback of Company's own shares pursuant to Section 69 of the Companies Act, 2013		
Retained earnings	3,700.93	2,213.58
-Retained earnings comprises of the amounts that can be distributed by the Company as dividends to its equity share holders		
Other items of other comprehensive income		
Remeasurement of defined benefit liability/ (asset), net of tax	21.69	20.98
- Pertains to the remeasurement of the net defined benefit liability/ (asset) recognised net of tax		
Total	11,217.16	9,729.10



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

14 Borrowings

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current		
<i>Secured - at amortised cost</i>		
Term loans from bank	1,377.75	1,941.43
Vehicle loans	22.66	33.07
	<u>1,400.41</u>	<u>1,974.50</u>
Current		
Current maturities of long-term borrowings	408.47	965.12
Bank overdraft	90.63	-
	<u>499.10</u>	<u>965.12</u>

Information about the Company's exposure to interest rate and liquidity risks are included in Note 36.

A Details of securities, terms and conditions on loans

1. Term loans from bank

HDFC Bank:

Represents term loan (including bank overdraft) of INR 4,300 (PY: INR 4,800) with outstanding balance of INR 960.22 (PY: INR 2,621.57) is to be re-paid in monthly instalments ranging from 75 to 84 months based on the repayment schedule provided by the bank commencing from 01 December 2016. The rate of interest charged by the bank ranged from 7.1% to 8.95% (PY: 8.95% to 9.80%).

Represents term loan of INR 826 (PY: Nil) with outstanding balance of INR 826 (PY: Nil) to be re-paid in monthly instalments of 48 months based on the repayment schedule provided by the bank commencing from 7th March 2023 after a moratorium of 1 year from the date of disbursement. The rate of interest charged by the bank ranged from 7.1% to 8.25%.

Primary Security: Equitable mortgage of lease hold rights on 304,302.47 Sq. Ft built up areas (3 cellars + Ground + 8 floors) on subleased land of 4,628.77 sq. ft. site in survey no. 1072, T.S.o:247/248, Ward no 17, Nagarampalem, Guntur.

Secondary Security: Hypothecation of stock and book debts less than 180 days. Margins on stock and book debts are 25%.
Corporate Guarantee of Lakshmana Hotels Pvt. Ltd.

2. Equipment Loans from financial institution (i.e. De Lage Landen Financial Services India (Private) Limited)

Various Equipment loans amounting to Rs. 2,114.00 (PY: Rs. 2,114.00) having balance outstanding as on balance sheet date Rs. Nil (PY: Rs. 273.72) is to be re-paid in monthly instalments ranging from 59 to 84 months with interest rate ranging from Nil (PY 7.57% to 11.25 % p.a.) based on the repayment schedule provided by the financial institution. The loans are secured by hypothecation of equipment's procured from the said loans and also secured by personal guarantees of promoter directors.

3. Vehicle Loans

Vehicle loans amounting to INR 52.05 (PY: INR 89.26) having balance outstanding as on balance sheet date INR 22.66 (PY: INR 33.07) is to be re-paid in equal monthly instalments ranging from 37 to 60 months with interest rate ranging from 8.70% to 9.80% p.a (PY 8.70% to 9.80 % p.a.) and is secured by hypothecation of vehicles financed by the bank.

B There are no continuing defaults in the repayment of the principal loan and interest amounts.

C For the year ended 31 March 2021, due to outbreak of Covid-19 pandemic, RBI vide circular DOR.No.BP.BC.47/21.04.048/2019-20 dated 27 March 2020 had directed banks and financial institutions to provide moratorium of 3 months to borrowers on all payments falling due between 1 March 2020 and 31 May 2020 and vide circular RBI/2019-20/244 DOR.No.BP.BC.71/ 21.04.048/ 2019-20 for all payments falling due between 1 June 2020 and 31 August 2020 to all eligible borrowers classified as standard. Accordingly, the Company had availed moratorium with respect to the principal and interest.

D The quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts.

15 Trade payables

Particulars	As at 31 March 2022	As at 31 March 2021
Total outstanding dues of micro enterprises and small enterprises	-	-
Total outstanding dues of creditors other than micro and small enterprises [^]	2,108.90	2,244.94
Total	<u>2,108.90</u>	<u>2,244.94</u>

All trade payables are 'current'. The average credit period taken is 30-60 days.

The Company's exposure to currency and liquidity risks related to trade payables is disclosed in Note 36.

[^] During the year ended 31 March 2022, the Company has sanctioned a loan of INR 100 lakhs to Dr. Ramesh Health and Educational Society ('Society'), wherein 2 of the Directors of the Company are also members of the Society, to be given in tranches. During the year, the Company has given one tranche of loan of INR 25 lakhs to the Society for running (capital expenditure and working capital purposes to establish) a Nursing College (RH College of Nursing). The loan carries an interest of @7.1% p.a. and is repayable at the end of 6 years along with interest.

Refer Note 34 for the balances payable to related parties.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

15.1 Trade payables ageing schedule

Particulars	Outstanding for following periods from due date of payment				Total*
	Less than 1	1-2 years	2-3 years	More than 3 years	
Balance as at 31 March 2022					
Micro, small and medium enterprises	-	-	-	-	-
Others	2,091.21	10.47	0.15	7.07	2,108.90
Total	2,091.21	10.47	0.15	7.07	2,108.90
Balance as at 31 March 2021					
Micro, small and medium enterprises	-	-	-	-	-
Others	2,205.41	17.68	10.01	11.84	2,244.94
Total	2,205.41	17.68	10.01	11.84	2,244.94

* Includes unbilled dues of INR 588.44 as at 31 March 2022 (INR 756.26 as at 31 March 2021).

15.2 Disclosures as required under the Micro, Small and Medium Enterprises Development Act, 2006 ("the Act") based on the information available with the Company are given below:

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
a) The principal amount remaining unpaid to any supplier at the end of the year	-	-
b) The interest due on the principal remaining outstanding as at the end of the year	-	-
c) The amount of interest paid under the Act, along with the amounts of the payment made beyond the appointed day during the year	-	-
d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act	-	-
e) The amount of interest accrued and remaining unpaid at the end of the year	-	-
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowances as a deductible expenditure under the Act	-	-

16 Provisions

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current		
Provision for employee benefits		
Net defined benefit liability - Gratuity (refer Note 33)	319.10	226.99
Total	319.10	226.99
Current		
Provision for employee benefits		
Net defined benefit liability - Gratuity (refer Note 33)	65.13	50.81
Total	65.13	50.81

17 Other financial liabilities

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current		
Security deposit	37.00	-
Total	37.00	-
Current		
Interest accrued but not due on borrowings*	10.44	13.60
Dues to creditors for capital goods	124.66	134.76
Dues to related party (refer Note 34)	27.55	23.59
Total	162.65	171.95

* The details of interest rates, repayment and other terms are disclosed in Note 14.

The Company's exposure to currency and liquidity risk related to the above financial liabilities is disclosed in Note 36.

18 Other liabilities

Particulars	As at 31 March 2022	As at 31 March 2021
Current		
Statutory dues payables	174.72	133.14
Total	174.72	133.14



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

19 Revenue from operations

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Revenue from hospital and medical services	18,675.62	13,203.19
Revenue from pharmacy	2,157.59	1,755.52
Other operating revenue		
Revenue from clinical & market studies	88.64	72.83
Revenue from canteen sales	358.37	267.36
Total	21,280.22	15,298.90

Refer Notes 19.1 and 19.2 below.

19.1 Category of Customers

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Cash	14,078.30	10,777.70
Credit	7,201.92	4,521.20
Total	21,280.22	15,298.90

19.2 Nature of treatment

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
In- patient	13,976.26	8,161.09
Out- patient	4,699.36	5,042.10
Total	18,675.62	13,203.19

20 Other income

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Interest income under the effective interest method on:		
Fixed deposits with banks	4.37	2.87
Lease deposits	6.66	5.71
Interest income on income tax refund	-	132.74
Interest income from others	-	3.82
Gain on sale of investments (net)	96.13	30.66
Financial assets at FVTPL - Net change in fair value	(44.98)	42.82
Guarantee commission income	-	1.47
Share of profit in limited liability partnership	30.00	30.00
Gain on reassessment of IND AS 116	1.36	2.89
Liabilities no longer required written back	17.00	2.35
Dividend on non-current investments	319.54	191.72
Other non-operating income	6.44	16.20
Total	436.52	463.25

21 Purchases of medicines and consumables

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Medicines and consumables	5,341.25	3,019.36
Total	5,341.25	3,019.36

22 Changes in inventories

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Opening stock	259.69	663.23
Closing stock	(315.88)	(259.69)
Total	(56.19)	403.54



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

23 Professional fees to consultant doctors

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Professional fees to consultant doctors	4,727.99	3,114.98
Total	4,727.99	3,114.98

24 Employee benefits expense

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Salaries and allowances	5,061.79	4,734.88
Contribution to provident and other funds (refer Note 33)	421.25	364.91
Staff welfare expense	29.99	6.91
Total	5,513.03	5,106.70

25 Finance cost

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Interest on bank borrowings	122.46	273.62
Interest on borrowings from financial institutions	7.95	42.10
Interest on lease liabilities (refer Note 31)	356.00	360.41
Other borrowing costs	0.50	3.14
Total	486.91	679.27

26 Depreciation and amortisation

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Depreciation on property, plant and equipment (refer Note 4)	1,001.32	981.33
Depreciation on right-of-use assets (refer Note 31)	178.98	256.96
Amortisation on intangible assets (refer Note 5)	21.22	16.51
Total	1,201.52	1,254.80



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

27 Other expenses

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Food and beverage	381.01	271.74
Power, water and fuel	503.19	411.43
Housekeeping, security and others	12.57	1.67
Legal, professional and other consultancy	97.13	148.38
Auditors remuneration (refer Note 27.1)	11.00	12.00
Rent (refer Note 31)	24.24	(38.75)
Repairs and maintenance - plant and equipment	40.74	28.84
Repairs and maintenance - building	47.41	81.80
Repairs and maintenance - computer equipment	11.99	12.21
Repairs and maintenance - medical equipment	214.99	181.70
Repairs and maintenance- others	180.38	116.31
Hospital maintenance	245.70	187.99
Advertising and promotional	139.71	86.23
Rates and taxes	86.75	65.20
Ineligible input tax credits	216.30	197.28
Allowances for credit losses on financial assets	182.00	353.87
Travelling and conveyance	37.15	27.12
Loss on disposal of property, plant and equipment (net)	14.97	4.28
Corporate Social Responsibility (refer Note 27.2)	3.41	25.00
Insurance	40.52	42.30
Communication	57.31	53.19
Donation & charity	1.75	11.50
Bad debts written off	60.36	82.23
Printing and stationery	102.29	56.46
Bank charges	69.40	57.61
Miscellaneous expenses	80.50	55.54
Total	2,862.77	2,533.13

27.1 Payment to auditors (net of goods and service tax)

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
For statutory audit	11.00	11.00
For tax audit	-	1.00
For reimbursement of expenses	-	-
Total	11.00	11.00

27.2 Details of Corporate Social Responsibility (CSR)

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
- Gross amount required to be spent during the year	3.41	17.14
- Amount of expenditure incurred	3.41	25.00
- Shortfall at the end of the year	-	-
- Total of previous year shortfall	-	-
- Reason for shortfall	Not applicable	Not applicable
- Nature of CSR activities	Eradicating hunger, poverty and malnutrition	Protection of natural heritage site
- Details of related party transactions	Not applicable	Not applicable
- Whether provision is made with respect to a liability incurred by entering into a contractual obligation	Not applicable	Not applicable
- Amount spent during the year on :		
Construction/acquisition of an asset	3.41	25.00
On purposes other than above	-	-
Total	3.41	25.00



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

28 Income taxes

(a) Income tax assets/(liability)

Particulars	As at 31 March 2022	As at 31 March 2021
Income tax payments, including taxes withheld	1,205.42	642.70
Less: Provision made towards tax liabilities	310.72	(10.80)
Net income tax assets/(liability) at the end	894.70	653.50

(b) Amount recognised in the statement of profit & loss

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Current tax	310.72	-
Current tax for earlier years	-	(10.80)
Deferred tax (including MAT credit entitlement)	(158.61)	515.63
Tax expense	152.11	504.83

(c) Amount recognised in other comprehensive income

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Current tax	-	-
Current tax for earlier years	-	-
Deferred tax (including MAT credit entitlement)	(0.28)	(8.09)
Tax expense	(0.28)	(8.09)

(d) Reconciliation of effective tax rate

The standard rate of corporation tax applied to reported profit is 27.82 per cent (2020-21: 27.82 per cent). The Company has not opted for concessional tax rate regime effective from financial year 2019-20.

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Profit before tax	1,639.46	(349.63)
Statutory income tax rate	27.82%	27.82%
Tax (asset)/ expenses	456.10	(97.27)
Tax effect of:		
Additional deduction on investment allowance	(130.63)	(21.14)
Non-deductible expenses/ permanent differences	(12.51)	11.91
Un-recognised deferred tax assets	-	-
Other temporary differences	(160.85)	611.33
Income tax expense	152.11	504.83

(e) Recognised deferred tax assets and liabilities

(i) Deferred tax assets and liabilities are attributable to the following:

Particulars	As at 31 March 2022	As at 31 March 2021
Deferred tax asset		
Allowances for credit losses	263.26	223.76
Provision for employee benefits	106.89	69.18
Lease liabilities	383.72	358.90
MAT credit entitlement receivable	524.14	403.08
Total deferred tax assets	1,278.01	1,054.92
Deferred tax liability		
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	903.70	838.94
Total deferred tax liability	903.70	838.94
Deferred tax asset (net)	374.31	215.98

The Company offsets deferred tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities related to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.



28 Income taxes (continued)

(ii) Movement in temporary differences

Particulars	Balance as at 1 April 2021	Recognised through retained earnings	Recognised in Statement of Profit and Loss	Recognised through other comprehensive income	Balance as at 31 March 2022
Deferred tax asset/(liabilities) in relation to:					
Allowances for credit losses	223.76	-	39.50	-	263.26
Provision for employee benefits	69.18	-	37.99	(0.28)	106.89
Lease liabilities	358.90	-	24.82	-	383.72
MAT credit entitlement receivable	403.08	-	121.06	-	524.14
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(838.94)	-	(64.76)	-	(903.70)
Total deferred tax asset/(liability)	215.98	-	158.61	(0.28)	374.31
Particulars	Balance as at 1 April 2020	Recognised through retained earnings	Recognised in Statement of Profit and Loss	Recognised through other comprehensive income	Balance as at 31 March 2021
Deferred tax asset/(liabilities) in relation to:					
Allowances for credit losses	111.50	-	112.26	-	223.76
Provision for employee benefits	158.19	-	(80.91)	(8.09)	69.18
Lease liabilities	316.30	-	42.60	-	358.90
MAT credit entitlement receivable	678.72	-	(275.64)	-	403.08
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(525.00)	-	(313.94)	-	(838.94)
Total deferred tax asset/(liability)	739.71	-	(515.63)	(8.09)	215.98

(iii) Deferred tax assets not recognised on grounds of prudence- Nil

(f) Tax losses carried forward - Nil



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

29 Contingent liabilities and commitments

Particulars	As at 31 March 2022	As at 31 March 2021
Contingent liability		
Value Added Tax (Refer Note (f) below)	16.99	-
Commitments		
Estimated amount of contracts remaining to be executed on capital account (net of advances) and not provided for (Refer Note (g) below)	3,467.55	0.65
Total	3,484.54	0.65

a. In the financial year 2014-15, a party filed a petition against the Company and a leasehold land owner on the grounds that the sub lease given by the leased owner was not valid. The Company is contesting the petition. Based on a legal opinion obtained, the Management does not reasonably expect that such legal action, when ultimately concluded and determined, will have a material and adverse effect on the Company's results of operations or financial conditions.

b. On 28th February 2019, the Hon'ble Supreme Court of India has delivered a judgment clarifying the principles that need to be applied in determining the components of salaries and wages on which Provident Fund (PF) contributions need to be made by establishments. Basis this judgment, the Company has re-computed its liability towards PF from the month of March 2019 and has paid PF as per Supreme Court judgement. In respect of the earlier periods/years, the Company has been legally advised that there are numerous interpretative challenges on the application of the judgment retrospectively. Based on such legal advice, the Management believes that it is impracticable at this stage to reliably measure the provision required, if any, and accordingly, no provision has been made towards the same. Necessary adjustments, if any, will be made to the books as more clarity emerges on this subject.

c. The Company does not have any long-term commitments or material non-cancellable contractual commitments/contracts, including derivative contracts for which there were any material foreseeable losses.

d. The Company was permitted to run a COVID Care Centre by the Krishna District Medical Health Officer in accordance with several measures undertaken by the Government of Andhra Pradesh after the outbreak of COVID-19 at Swarna Palace Hotel, Vijayawada. On 09 August 2020, a fire accident took place at Swarna Palace Hotel. A written report was submitted by the Tahsildar - Vijayawada East, at the Governorpet Police Station, Vijayawada regarding the said fire accident which was registered as FIR No.173 of 2020 of Governorpet Police Station, under Sections 304 (II), 308 read with 34 of IPC. FIR was filed against the Management of the Company and Swarna Palace Hotel. Several writ petitions have been filed by the Management of the Company to quash the proceedings in FIR No.173 of 2020; however, the investigations have been allowed to continue. Investigations are ongoing and the final report is yet to be filed. The Company has filed a discrimination petition against the Government in the Hon'ble High Court. The Company has reviewed this litigation and based on the legal advice, the Company believes that it is impracticable at this stage to reliably measure the amount of provision required, if any. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position.

e. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liability where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position. The Company does not expect any reimbursement in respect of the above contingent liabilities.

f. The Company has received a demand order from the Commercial Taxes Department of Government of Andhra Pradesh in respect of Value Added Tax (VAT) pertaining to the financial years 2013-14, 2014-15 and 2015-16 based on the scrutiny carried out by the department. The Company is contesting the case and has paid INR 4.25 lakhs under protest in this regard.

g. The Company has commitment to purchase the balance 1,772,992 equity shares of Sanghmitra Hospitals Private Limited from the other shareholders for INR 346,755,376. Post this balance acquisition, Sanghmitra Hospitals Private Limited would become a wholly-owned subsidiary.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

30 Earnings per share

A. Basic earnings / (loss) per share

The calculation of profit/(loss) attributable to equity share holders and weighted average number of equity shares outstanding for the purpose of basic earnings / (loss) per share calculations are as follows:

i) Net profit/ (loss) attributable to equity share holders (basic)		
Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Net profit / (loss) for the year, attributable to the equity share holders	1,487.35	(854.46)

ii) Weighted average number of equity shares (basic)		
Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Opening balance (refer Note 13)	107.86	107.86
Weighted average number of equity shares of INR 10 each for the year	107.86	107.86
Earnings/ (loss) per share, basic	13.79	(7.92)

B. Diluted earnings / (loss) per share

The calculation of profit / (loss) attributable to equity share holders and weighted average number of equity shares outstanding, after adjustment for the effects of all dilutive potential equity shares is as follows:

i) Net profit/ (loss) attributable to equity share holders diluted)		
Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Net profit / (loss) for the year, attributable to the equity share holders	1,487.35	(854.46)

ii) Weighted average number of equity shares (diluted)		
Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Weighted average number of equity shares of INR 10 each for the year (diluted)	107.86	107.86
Earnings / (loss) per share, diluted	13.79	(7.92)

31 Leases

The Company has taken hospital premises, medical equipments and certain premises for staff accommodation on lease from various parties. The leases typically run for a period of 1 year - 7 years. Lease payments are renegotiated nearing the expiry to reflect market rentals.

(i) Lease liabilities

C. Following are the changes in the lease liabilities for the year ended 31 March 2022 and 31 March 2021:

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Opening balance	4,009.84	4,157.17
Additions	86.09	20.95
Reversals	(10.11)	(67.90)
Finance cost accrued during the period (refer Note 25)	356.00	360.41
Payment of lease liabilities	(444.43)	(460.79)
Closing balance	3,997.39	4,009.84
Non-current lease liabilities	3,879.05	3,909.61
Current lease liabilities	118.34	100.23

(ii) Maturity analysis – contractual undiscounted cash flows

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Less than one year	455.17	440.08
One to five years	1,891.65	1,780.60
More than five years	6,356.82	6,825.62
Total undiscounted lease liabilities	8,703.64	9,046.30



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

31 Leases (continued)

(iii) Right-of-use assets

Right-of-use assets are presented on the balance sheet.

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Gross carrying value		
Opening balance	3,168.96	3,210.67
Addition to right-of-use assets	86.08	20.95
Deletion to right-of-use assets	(8.75)	(62.66)
Total gross carrying value	3,246.29	3,168.96
Accumulated Depreciation		
Opening balance	449.21	192.25
Depreciation for the year (refer Note 26)	178.98	256.96
Total accumulated Depreciation	628.19	449.21
Net Balance	2,618.10	2,719.75

(iv) Amounts recognised in statement of profit or loss

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Lease rental expenses for lease where Ind AS 116 is not applicable	24.24	(38.75)
Interest on lease liabilities	356.00	360.41
Depreciation on right-of-use assets	178.98	256.96

(v) Amounts recognised in statement of cash flows

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Total cash outflow for leases	444.43	460.79

The Company has benefited from a 3 month waiver of lease payments on buildings in India during the year ended 31 March 2021. The waiver of lease payments of INR 0.68 crore was accounted for as a negative variable lease payment in the statement profit and loss during the year ended 31 March 2021. The Company has derecognised the part of the lease liability that has been extinguished by the forgiveness of lease payments, consistent with the requirements of Ind AS 109:3.3.1.

32 Segment reporting

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Medical and Healthcare Services'. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements.

The Company operates in India and revenue generations is from a wide spread of the customers and hence the group wide disclosures of major customers are not applicable.



33 Employee benefits

i) Defined contribution plan

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund ('PF') and Employees State Insurance scheme ('ESI') which is a defined contribution plan. The Company has no obligations other than to make the specified contributions. The contribution to PF and ESI charged to the Statement of profit and loss is INR 244.23 (PY: INR 209.80) and INR 69.59 (PY: INR 67.57), respectively.

ii) Defined benefit plan

The Company has a defined benefit gratuity plan as per the Payment of Gratuity Act, 1972 ('Gratuity Act'). Under the Gratuity Act, employee who has completed five years of service is entitled to specific benefit. The gratuity benefit provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 / 30 days' salary payable for each completed year of service. The gratuity plan is a funded plan and the Company makes contributions to recognized funds in India. Liability with regard to this plan is determined by an actuarial valuation as at the end of the year and are charged to the Statement of profit and loss.

Following table sets out the status of employee benefits as at balance sheet date

Particulars	As at 31 March 2022	As at 31 March 2021
Present value of defined benefit obligation	532.68	416.66
Present value of plan assets	(148.45)	(138.86)
Net liability recognised	384.23	277.80

A. Funding

The Company has purchased an insurance policy to provide for payment of gratuity to the employees. Every year, the insurance Company carries out a funding valuation based on the latest employee data provided by the Company. Any deficit in the assets arising as a result of such valuation is funded by the Company.

The following tables summarise the components of net benefit expense recognised in the statement of profit or loss and the funded status and amounts recognised in the balance sheet for the respective plans:

B. (i) Reconciliation of the present value of defined benefit obligation

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Balance at the beginning of the year	416.66	398.68
Current service cost	78.63	62.05
Interest cost	28.79	25.49
Benefits paid		(49.75)
Actuarial (gains)/ loss recognised in the other comprehensive income		
- experience adjustments	22.45	56.80
- changes in financial assumptions	(13.84)	(76.61)
Balance at the end of the year	532.69	416.66

(ii) Reconciliation of the present value of plan assets

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Balance at the beginning of the year	138.86	179.35
Contributions paid into the plan by employer	-	-
Benefits paid	-	(49.75)
Expected return on plan assets	9.60	9.26
Actuarial gain/ (loss) on plan assets	148.46	138.86
Balance at the end of the year	384.23	277.80
Net defined benefit liability / (asset)		
Current	65.13	50.81
Non-current	319.10	226.99

C. (i) Expense recognized in the Statement of profit and loss

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Current service cost	78.63	62.05
Interest cost	28.79	25.49
Interest income	-	-
	107.42	87.54

(ii) Remeasurements recognised in Other comprehensive income

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Actuarial (gain)/ loss on defined benefit obligation	8.61	(19.81)
Return on plan assets excluding interest income	(9.60)	(9.26)
	(0.99)	(29.07)



33 Employee benefits (continued)

D. Actuarial Valuation

The present value of the defined benefit obligation, and the related current service cost and past service cost, were measured using the projected unit credit method. The defined benefit plan typically exposes the Company to actuarial risks such as: investment risk, interest rate risk, longevity risk and salary risk.

Investment risk	The present value of the defined benefit plan liability denominated in Indian Rupee is calculated using a discount rate determined by reference to market yields at the end of the reporting period on government bonds. For other defined benefit plans, the discount rate is determined by reference to high quality corporate bond yields when there is a deep market for such bonds; if the return on plan asset is below this rate, it will create a plan deficit. Currently the plan in India is investments in government securities and other debt instruments.
Interest rate risk	A decrease in the bond interest rate will increase the plan liability
Longevity risk	The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
Salary risk	The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability

Assumptions used to determine benefit obligations:

Principal actuarial assumptions at the reporting date (expressed as weighted average)

Particulars	As at 31 March 2022	As at 31 March 2021
Financial assumptions		
Discount rate	7.33%	6.91%
Future salary growth rate	4.00%	4.00%
Attrition rate	10.00%	10.00%
Return on Plan assets	6.91%	9.25%
Mortality table	IALM (2012-14)	IALM (2012-14)

Assumptions regarding future mortality experience are set in accordance with the published statistics by the Life Insurance Corporation of India.

The Company assesses these assumptions with its projected long-term plans of growth and prevalent industry standards. The discount rate is based on the government securities yield.

Gratuity is applicable only to employees drawing a salary in Indian rupees and there are no other foreign defined benefit gratuity plans.

F. Maturity profile of the defined benefit obligation

Expected cash flows over the next (valued on undiscounted basis):

Particulars	As at 31 March 2022	As at 31 March 2021
Within 1 year	65.13	50.81
2 to 5 years	253.27	188.11
6 to 10 years	242.82	190.15

The weighted average duration of the defined benefit obligation is 7.00 years (PY: 9.88 years).

iv) Sensitivity Analysis

Significant actuarial assumptions for the determination of the defined benefit obligation are discount rate, expected salary increase and withdrawal rate. Reasonably possible changes at the reporting date to one of the actuarial assumptions, affected the defined benefit obligation by the amounts shown below:

Particulars	31 March 2022		31 March 2021	
	Increase	Decrease	Increase	Decrease
Discount Rate (1% movement)	(30.35)	34.13	(24.56)	27.70
Future Salary Growth (1% movement)	35.07	(31.67)	28.25	(25.46)
Withdrawal rate (1% movement)	5.94	(6.68)	3.97	(4.52)

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the changes in assumptions would occur in isolation of one another as some of the assumptions may be correlated. In presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet. There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

v) The Company has to pay INR 65.13 (PY INR 50.81) as contribution towards its defined benefit obligation in the next financial year.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

34 Related parties

(i) Names of related parties and description of relationship with the Company:

(a) Holding Company

(b) Enterprise exercising significant influence

(c) Subsidiary Company

Aster DM Healthcare Limited
Union Investment Private Limited, Mauritius
Aster Ramesh Duhita LLP
Sanghamitra Hospitals Private Limited
Komali Fertility Centre LLP (Formerly known as Ramesh Fertility Centre LLP)

(d) Key managerial personnel and their relatives (KMP)

Dr. P Ramesh Babu

Mr. P Ravi Kiran

Mr. Nagendra Kumar Sagi

Mr. Suggula Hari Krishna

Managing Director
Director [Chief Financial Officer (till 7 November 2020)]
Company Secretary
Chief Financial Officer (w.e.f. 04.03.2022)

(e) Other Non Executive Directors

Sreenath Pocha Reddy

Thadathil Wilson

Devanand Kolothodi (w.e.f. 04.03.2022)

MR. Sunil Kumar (w.e.f. 04.03.2022)

Maddipati Sita Rama Mohan Rao

(f) Other Independent Directors

Abdurahman Kartholiparamba

K. Bapaiah Chowdary

Chairman and Director

(g) Relatives of KMP

Mr. P Subba Rao

Mrs. P S Kamala Devi

Mrs. M Madhusmitha

Mr. P Mahendra Babu

Mrs. K Madhumathi

Dr. P Vasundhara Devi

Mrs. P Madhuri

Mr. R Chalapathi Rao

Mrs. R Radhabai

Mrs. M Sailaja

Mrs. P Maha Lakshmi

Mr. P V. Ravi Kishore

Mr. P. Murali Mohan

Father of Managing Director
Mother of Managing Director
Daughter of Managing Director
Brother of Managing Director
Sister of Managing Director
Sister of Chairman and Director
Wife of Mr. P Mahendra Babu
Father in law of Managing Director
Mother in law of Managing Director
Daughter-in-law of Chairman
Wife of Managing Director
Brother of Managing Director
Brother of Managing Director

(ii) Related party transactions:

The Company has entered into the following transactions with related parties during the year ended 31st March 2022:

Transactions with key managerial persons including Directors:

Particulars	Name of the Related Party	For the year ended 31 March 2022	For the year ended 31 March 2021
Rent	Dr P Ramesh Babu	44.92	37.84
Short term employee benefits*	Dr P Ramesh Babu	186.40	192.00
	Mr. P Ravi Kiran	16.50	71.50
	Total	202.90	263.50

Balances receivable / (payable) with key managerial persons including Directors:

Particulars	Name of the Related Party	As at 31 March 2022	As at 31 March 2021
Rent deposit^	Dr P Ramesh Babu	30.00	30.00

* The above figure does not include provision for gratuity as the same is determined for the Company as a whole based on an actuarial valuation.

^ Actual payout done towards the rent deposit.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

34 Related parties (continued)

Transactions with related parties other than key managerial persons :

Particulars	Name of the Related Party	For the year ended 31 March 2022	For the year ended 31 March 2021
Rent Paid	P. Mahalakshmi	14.08	11.62
	Dr. P. Vasundhara Devi	42.48	36.29
	P. Subba Rao	3.54	18.14
	P.S. Kamala Devi	21.24	18.14
	K. Madhumathi	42.48	36.29
	M. Sailaja	29.31	25.04
	P. Mahendra Babu	42.48	36.29
	P. Murali Mohan	8.85	-
	P. V. Ravi Kishore	8.85	-
	Total	213.31	181.81
License fee income	Aster Ramesh Duhita LLP	-	3.00
	Komali fertility Centre LLP	-	3.74
	Total	-	6.74
Other medical services income	Aster Ramesh Duhita LLP	12.00	9.00
	Komali fertility Centre LLP	15.00	9.38
	Total	27.00	18.38
Purchase of pharmacy and medical consumables	Aster DM Healthcare Limited, India	-	0.16
Professional services received	Aster DM Healthcare Limited, India	16.35	4.80
Reimbursement of travelling expenses	Aster DM Healthcare Limited, India	-	0.05
Marketing exp	Aster DM Healthcare Limited, India	0.83	3.18
Other service	Aster DM Healthcare Limited, India	0.20	11.31
	Total	17.37	19.50
Purchase of pharmacy and medical consumables	Sanghamitra Hospitals Private Limited	27.99	-
Professional services received	Sanghamitra Hospitals Private Limited	13.50	-
Sale of pharmacy and medical consumables	Sanghamitra Hospitals Private Limited	(12.17)	-
Professional services given	Sanghamitra Hospitals Private Limited	(22.00)	-
Other service given	Sanghamitra Hospitals Private Limited	(24.04)	-
	Total	(16.72)	-
Remuneration paid	Mrs P Mahalakshmi	8.89	7.43
	Dr. P. Vasundhara Devi	5.97	3.37
	P. Madhusmitha	5.88	5.32
	P. Mahendra Babu	40.78	26.25
	Nagendra Kumar Sagi	13.85	11.34
	Suggula Hari Krishna	22.05	-
	Total	97.42	53.71
Advance for expenditure	Aster Ramesh Duhita LLP	4.55	8.35
Investment	Sanghamitra Hospitals Private Limited [^]	2,476.65	-
Dividend received	Sanghamitra Hospitals Private Limited	319.54	191.72
Share of profit from associates & subsidiaries	Komali fertility Centre LLP	30.00	30.00

[^] Excludes stamp duty charges incurred amounting to INR 8.62 lakhs.

Balances receivable/ (payable) with related parties other than key managerial persons:

Particulars	Name of the Related Party	As at 31 March 2022	As at 31 March 2021
Purchase of pharmacy and medical consumables	Aster DM Healthcare Limited, India	-	0.28
Professional services received	Aster DM Healthcare Limited, India	(26.79)	-
Reimbursement of travelling expenses	Aster DM Healthcare Limited, India	-	0.93
Staff recruitment services received	Aster DM Healthcare Limited, India	-	11.07



34 Related parties (continued)

Balances receivable/ (payable) with related parties other than key managerial persons (contd.)

Particulars	Name of the Related Party	As at 31 March 2022	As at 31 March 2021
Other services	Aster DM Healthcare Limited, India	-	11.30
Purchase of pharmacy and medical consumables	Sanghamitra Hospitals Private Limited	(0.76)	-
Advance paid towards capital contribution	Aster Ramesh Duhita LLP	43.91	39.36
Rent Deposits paid	Mrs P. Mahalakshmi	5.61	5.61
	Dr. P. Vasundhara Devi	30.00	30.00
	P. Subba Rao	15.00	15.00
	Kamala Devi	15.00	15.00
	K Madhumathi	30.00	30.00
	P. Mahendra Babu	30.00	30.00
	Total	125.61	125.61
Remuneration payable	Nagendra Kumar Sagi	0.91	-
	Suggula Hari Krishna	1.88	-
	Total	2.79	-
Investment	Aster Ramesh Duhita LLP	47.75	47.75
	Komali fertility Centre LLP	40.00	40.00
	Sanghamitra Hospitals Private Limited ^a	5,383.13	2,915.10
	Total	5,470.88	3,002.85

^a Excludes stamp duty charges incurred amounting to INR 8.62 lakhs.

Note

- The KMP and relatives of KMP are covered by the Company's gratuity policy and are eligible for compensated absences along with other employees of the Company. The proportionate amount of gratuity and compensated absences cost pertaining to individuals have not been included in the aforementioned disclosures as these are not determined on individual basis.
- For certain loans availed by the Company, KMP of the Company have given personal guarantee. Refer Note 14.

35 Capital Management

The Company's policy is to maintain a stable capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors capital on the basis of return on capital employed as well as the debt to total equity ratio. For the purpose of debt to total equity ratio, debt considered is long-term and short-term borrowings. Total equity comprise of issued share capital and all other equity reserves.

The capital structure as of 31 March 2022 and 31 March 2021 was as follows:

Particulars	As at 31 March 2022	As at 31 March 2021
Total equity attributable to the equity shareholders of the Company	12,295.74	10,807.68
As a percentage of total capital	87%	79%
Long-term borrowings including current maturities	1,808.88	2,939.62
Bank overdraft	90.63	-
Total borrowings	1,899.51	2,939.62
As a percentage of total capital	13%	21%
Total capital (Equity and Borrowings)	14,195.25	13,747.30



36 Financial instruments - Fair values and risk management

A. Accounting classifications and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy

31 March 2022

	Note	Carrying amount			Fair value			
		Mandatorily at FVTPL	Financial assets - Amortised cost	Other financial liabilities at amortised cost	Total Carrying value	Level 1	Level 2	Level 3
Assets								
Financial assets measured at fair value								
Investments	6	602.17	-	-	602.17	602.17	-	-
		602.17	-	-	602.17	602.17	-	-
Financial assets not measured at fair value								
Investments	6	5,479.50	-	-	5,479.50	-	-	-
Trade receivables	8	-	1,294.59	-	1,294.59	-	-	-
Cash and cash equivalents	9	-	61.10	-	61.10	-	-	-
Other Financial Assets	10	-	408.08	-	408.08	-	-	-
Total		5,479.50	1,763.77	-	7,243.27	-	-	-
Liabilities								
Financial liabilities not measured at fair value								
Borrowings	14	-	-	1,899.51	1,899.51	-	-	-
Lease liabilities	31	-	-	3,997.39	3,997.39	-	-	-
Trade payables	15	-	-	2,108.90	2,108.90	-	-	-
Other financial liabilities	17	-	-	199.65	199.65	-	-	-
Total		-	-	8,205.45	8,205.45	-	-	-

31 March 2021

	Note	Carrying amount			Fair value			
		Mandatorily at FVTPL	Financial assets - Amortised cost	Financial liabilities - amortised cost	Total	Level 1	Level 2	Level 3
Financial assets measured at fair value								
Investments	6	2,367.77	-	-	2,367.77	2,367.77	-	-
		2,367.77	-	-	2,367.77	2,367.77	-	-
Financial assets not measured at fair value								
Investments	6	-	3,002.85	-	3,002.85	-	-	-
Trade receivables	8	-	1,105.73	-	1,105.73	-	-	-
Cash and cash equivalents	9	-	724.80	-	724.80	-	-	-
Other Financial Assets	10	-	410.87	-	410.87	-	-	-
		-	5,244.25	-	5,244.25	-	-	-
Financial liabilities not measured at fair value								
Borrowings	14	-	-	2,939.62	2,939.62	-	-	-
Lease liabilities	31	-	-	4,009.84	4,009.84	-	-	-
Trade payables	15	-	-	2,244.94	2,244.94	-	-	-
Other financial liabilities	17	-	-	171.95	171.95	-	-	-
Total		-	-	9,366.35	9,366.35	-	-	-

Note: The Company has not disclosed the fair values for financial instruments such as cash and cash equivalents, trade receivables, trade payables etc., because their carrying amounts are a reasonable approximation of fair value. The fair values of the units of mutual fund schemes are based on net asset value at the reporting date.



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

36 Financial instruments - Fair values and risk management (continued)

B Financial risk management

The Company's activities expose it to a variety of financial risks: credit risk, market risk and liquidity risk.

i) Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the risk management framework.

The Company's board of directors oversee how management monitors compliance with the risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The board is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the board of directors.

ii) Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and other financial instruments.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from trade receivables are monitored on a continuous basis by the receivables team.

The Company always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtors and an analysis of the debtors' current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate, and an assessment of both the current as well as the forecast direction of conditions at the reporting date.

The maximum exposure to the credit risk at the reporting date is primarily from trade receivables amounting to INR 1,249.59 (PY: INR 1,105.73).

The movement in lifetime ECL in respect of trade and other receivables during the year was as follows:

	As at	
	31 March 2022	31 March 2021
Allowance for credit loss		
Balance at the beginning	804.30	401.64
Impairment loss recognised	142.00	402.66
Balance at the end	946.30	804.30

No single customer accounted for more than 10% of the revenue as of 31 March 2022 and 31 March 2021. There is no significant concentration of credit risk.

Credit risk on cash and cash equivalent and other bank balances is limited as the Company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies.



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

36 Financial instruments - Fair values and risk management (continued)

iii)

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. Ultimate responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework for management of the Company's short, medium and long-term funding and liquidity management requirements. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2022:

Particulars	Less than 1 Year	More than 1 year	Total
Trade payables	2,108.90	-	2,108.90
Current Borrowings	499.10	-	499.10
Non current borrowing	-	1,400.41	1,400.41
Lease liabilities	118.34	3,879.05	3,997.39
Other financial liabilities	199.65	-	199.65
Total	2,925.99	5,279.46	8,205.45

The Company is using the cash inflows from the financial assets and the available bank facilities to manage the liquidity. The table below provides the cash inflows from significant financial assets as of 31 March 2022:

Particulars	Less than 1 year	More than 1 year	Total
Cash and Cash equivalents	61.10	-	61.10
Investments	602.17	5,479.50	6,081.67
Trade receivables	1,294.59	-	1,294.59
Other financial assets	111.00	297.08	408.08
Total	2,068.86	5,776.58	7,845.44

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2021:

Particulars	Less than 1 Year	More than 1 year	Total*
Trade payables	2,244.94	-	2,244.94
Current Borrowings	965.12	-	965.12
Non current borrowings	-	1,974.50	1,974.50
Lease liabilities	100.23	3,909.61	4,009.84
Other financial liabilities	171.95	-	171.95
Total	3,482.24	5,884.11	9,366.35



36 Financial instruments - Fair values and risk management (continued)

The Company is using the cash inflows from the financial assets and the available bank facilities to manage the liquidity. The table below provides the cash inflows from significant financial assets as of 31 March 2021:

Particulars	Less than 1 year	More than 1 year	Total
Cash and Cash equivalents	724.80	-	724.80
Investments	2,367.77	3,002.85	5,370.62
Trade receivables	1,105.73	-	1,105.73
Other financial assets	138.18	272.69	410.87
Total	4,336.48	3,275.54	7,612.02

Financial assets of INR. 7,845.44 lakhs as at 31 March 2022 carried at amortised cost is in the form of cash and cash equivalents, deposits, etc. where the Company has assessed the counterparty credit risk. Trade receivables of INR. 1,294.59 lakhs as at 31 March 2022 carried at amortised cost and is valued considering provision for allowance using expected credit loss method (if any). In addition to the historical pattern of credit loss, we have considered the likelihood of increased credit risk and consequential default considering emerging situations due to COVID-19. This assessment is not based on any mathematical model but an assessment considering the impact immediately seen in the demand outlook and the financial strength of the customers in respect of whom amounts are receivable. The Company has specifically evaluated the potential impact with respect to Healthcare service sector. The Company closely monitors its customers who are being impacted. Also a substantial portion of the financial asset is related to investments in subsidiary companies (INR 5,479.50 Crore) wherein Management has considered the impact of COVID-19 on the projections while doing its assessment for impairment testing.

iv)

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates, interest rates and equity prices.

Interest rate risk

The Company is exposed to interest rate risk because the Company borrows funds at both fixed and floating interest rates. The Company's significant interest rate risk arises from long-term borrowings with variable interest rates, which expose the Company to cash flow interest rate risk. The interest rate on the Company's financial instruments is based on market rates. The Company monitors the movement in interest rates on an ongoing basis. The risk is managed by the Company by maintaining an appropriate mix between fixed and floating rate borrowings.

The exposure of the Company's borrowing to interest rate changes at the end of the reporting period are as follows:

Financial liabilities (bank borrowings)	31 March 2022	31 March 2021
Variable rate long term borrowing including current maturities and overdraft	1,899.51	2,939.62

Sensitivity analysis

Particulars	Impact on profit or (loss)		Impact on equity, net of tax	
	As at 31 March 2022	As at 31 March 2021	As at 31 March 2022	As at 31 March 2021
1% increase in MCLR rate	(19.00)	(29.40)	(19.00)	(29.40)
1% decrease in MCLR rate	19.00	29.40	19.00	29.40

The analysis is prepared assuming the amount of liability outstanding at the reporting date was outstanding for the whole year. A one per cent increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates. The Company's sensitivity to interest rates has increased in the current year due to the additional variable rate long term borrowings taken during the year.

Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

37 Investments, loans, guarantees and security

(a) The Company has made investment in the following companies / limited liability partnerships:

Entity	As at 1 April 2021	Allotment/Pur- chases during the year	Sold During the year	Impairment/ Write off	As at 31 March 2022
Investment in equity instruments					
Aster Ramesh Duhita LLP	47.75	-	-	-	47.75
Sanghamitra Hospitals Private Limited	2,915.10	2,476.65	-	-	5,391.75
Komali Fertility Centre LLP (Formerly known as Ramesh Fertility Centre LLP)	40.00	-	-	-	40.00
Total Investments	3,002.85	2,476.65	-	-	5,479.50

Particulars	As at 1 April 2020	Allotment/Pur- chases during the year	Sold During the year	Impairment/ Write off	As at 31 March 2021
Investment in equity instruments					
Aster Ramesh Duhita LLP	47.75	-	-	-	47.75
Sanghamitra Hospitals Private Limited	2,915.10	-	-	-	2,915.10
Komali Fertility Centre LLP (Formerly known as Ramesh Fertility Centre LLP)	40.00	-	-	-	40.00
Total Investments	3,002.85	-	-	-	3,002.85

(b) The Company has given guarantees to the following entities:

Particulars	As at 1 April 2021	Movement	As at 31 March 2022	Purpose of guarantees
Sanghamitra Hospitals Private Limited	750.00	(750.00)	-	Corporate guarantee given to Axis Bank to get Term Loan and Working Capital Facility for Sanghamitra Hospitals Private Limited. All the term loans obtained were repaid during FY21. All the said facilities were closed during the year.
Total	750.00	(750.00)	-	

Particulars	As at 1 April 2020	Movement	As at 31 March 2021	Purpose of guarantees
Sanghamitra Hospitals Private Limited	1,733.00	(983.00)	750.00	Corporate guarantee given to Axis Bank to get Term Loan and Working Capital Facility for Sanghamitra Hospitals Private Limited. All the term loans obtained were repaid during the year.
Total	1,733.00	(983.00)	750.00	



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated

- 38 The Company has established a comprehensive system of maintenance of information and documents as required by the transfer pricing legislation under sections 92-92F of the Income Tax Act, 1961. Since the law requires existence of such information and documentation to be contemporaneous in nature, the Company is in the process of updating the documentation for the international transactions entered into with associated enterprises during the financial period and expects such records to be in existence latest by the date of filing its income tax return as required by the law. The Management is of the opinion that its international transactions are at arm's length so that the aforesaid legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for taxation.
- 39 The Indian Parliament has approved the Code on Social Security, 2020 and Code on Wages, 2019 ['Codes'] relating to employee benefits during employment and post-employment benefits in September 2020 and the same has received Presidential Assent. The Codes have been published in the Gazette of India. However, the date on which the Codes will come into effect has not yet been notified. The Company will give appropriate impact in its financial statements in the period in which the Code becomes effective and the related rules are published.

40 Financial ratios				
Ratio	Methodology (Refer Notes below)	For the year ended 31 March 2022	For the year ended 31 March 2021	Explanation if variance exceeds 25%
a) Current ratio	Current assets/ Current liabilities	0.84	1.31	Due to sale of current investments in the current year.
b) Debt-equity ratio	Total debt/ Shareholder's equity	0.43	0.36	NA
c) Debt service coverage ratio	Earnings available for debt service/ Debt service	1.15	0.40	Due to increase in the revenue and cost optimisation.
d) Return on equity	Net profit after taxes/ Average shareholder's equity	0.13	(0.08)	Due to increase in the revenue and cost optimisation.
e) Inventory turnover ratio	Cost of goods sold/ Average inventory	18.36	7.42	Due to increase in the operations of the Company.
f) Trade receivables turnover ratio	Revenue from operations/ Average accounts receivables	17.73	8.14	Due to increase in the operations of the Company and improved recoveries/collections.
g) Trade payables turnover ratio	Total purchases/ Average trade payables	2.45	1.25	Due to increase in the operations of the Company.
h) Net capital turnover ratio	Net sales/ Working capital	(41.33)	13.64	Due to sale of current investments in the current year.
i) Net profit ratio	Net profit/ Net sales	0.07	(0.06)	Due to increase in the operations of the Company, increase in revenue and cost optimisation.
j) Return on capital employed	Earnings before interest and taxes/ Capital employed	0.10	(0.01)	Due to increase in the operations of the Company, increase in revenue and cost optimisation.
k) Return on investment	Dividend income, net gain on sale of investments and net fair value gain over average investments	0.06	0.06	NA

Notes:

Total debt = Borrowings + Lease liabilities - Cash & cash equivalents - Current investments

Earnings available for debt service = Net profit before taxes + Non-cash operating expenses like depreciation and amortisations - Other income + Interest + Other adjustments (such as loss on sale of property, plant and equipment, fair valuation of put options, if any)

Debt service = Interest + Lease payments + Principal repayments

Net profit = Net profit after tax

Capital employed = Tangible net worth + Total debt

Earnings before interest and taxes = Net profit before taxes - Other income + Interest + Other adjustments (such as loss on sale of property, plant and equipment, fair valuation of put options, if any)




Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts in INR lakhs, unless otherwise stated


41 Additional disclosures

- a) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property during and as at 31 March 2022 and 31 March 2021 ('the reporting periods').
- b) The Company has not revalued any of its Property, plant and equipment, Intangible assets and Right-to-use-assets during the reporting periods.
- c) There are no transactions and balances with companies which have been removed from the Register of Companies [struck off companies] during and as at the reporting periods.
- d) The Company has not traded / invested in Crypto currency during the reporting periods.
- e) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period as at the reporting periods.
- f) The Company has not advanced or loaned or invested funds during the reporting periods to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (i) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- g) The Company has not received any fund during the reporting periods from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- h) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the reporting periods in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- i) The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person that are:
- (i) repayable on demand; or
 - (ii) without specifying any terms or period of repayment.
- j) The Company is not declared as willful defaulter by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof or other lender in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India.
- k) The Company has complied with the number of layers for its holding in downstream companies prescribed under clause (87) of Section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.




for and behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U73100AP1995PTC020491


Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
20 May 2022


CA. Suggula Hari Krishna
Chief Financial Officer

Vijayawada
20 May 2022


Mr. M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
20 May 2022


S. Nagendra Kumar
Company Secretary
Membership No. A33490
Vijayawada
20 May 2022